Based on the available data and the recent FDA approval, the panel consensus was to include pembrolizumab as a first-line chemotherapy for patients who are cisplatin-ineligible with locally advanced or metastatic disease. Pembrolizumab was added as a category 2A option for the following settings:

- Bladder Cancer
- Upper GU Tract Tumors: Renal Pelvis
- Upper GU Tract Tumors: Urothelial carcinoma of the ureter
- Urothelial Carcinoma of the Prostate
- Primary Carcinoma of the Urethra (urothelial carcinomas only)

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/Reference</th>
<th>Vote</th>
</tr>
</thead>
</table>
| BL-H 2 of 4 Internal request | Based on the available data and the recent FDA approval, the panel consensus was to include pembrolizumab as a first-line chemotherapy for patients who are cisplatin-ineligible with locally advanced or metastatic disease. Pembrolizumab was added as a category 2A option for the following settings:  
  - Bladder Cancer  
  - Upper GU Tract Tumors: Renal Pelvis  
  - Upper GU Tract Tumors: Urothelial carcinoma of the ureter  
  - Urothelial Carcinoma of the Prostate  
  - Primary Carcinoma of the Urethra (urothelial carcinomas only) | YES | NO | ABSTAIN | ABSENT |
| Internal request Review the data for the inclusion of pembrolizumab as a first-line chemotherapy for patients who are cisplatin-ineligible with locally advanced or metastatic disease. | | 20 | 0 | 3 | 5 |
| External request Submission request from Merck & Co., Inc., to consider updating the NCCN guidelines to include pembrolizumab in the first-line standard regimens for cisplatin ineligible patients with locally advanced or metastatic urothelial carcinoma. | | 20 | 0 | 3 | 5 |

See Submission for references.